Targeting PI3K Remains Complex in Cancer Therapy

Video
Conference|San Antonio Breast Cancer Symposium (SABCS)

Dr. Lewis Cantley discusses targeting the PI3K pathway in breast cancer and the importance of managing ambient insulin levels during therapy.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Dr. Lewis Cantley discusses targeting the PI3K pathway in breast cancer and the importance of managing ambient insulin levels during therapy.

      Recent Videos
      Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
      Clinical Data May Support PARP Inhibition in Somatic BRCA-Mutant TNBC
      Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
      Considerations After Initial CDK4/6 Inhibition in HR+/HER2- Breast Cancer
      T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
      T-DXd May Be the Preferred ADC in HR+/HER2– Breast Cancer
      The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
      Gene Assay Can Guide Chemo Strategies in Older Breast Cancer Population
      Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
      Targeted Tool May Optimize Infusion Therapy Delivery in Breast Cancer
      Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
      Pivotal Presentations That May Shape the Breast Cancer Standard of Care
      Trial Insights from TROPiCS-02 and DESTINY-Breast06 in HR+/HER2– Breast Cancer
      Trial Insights from TROPiCS-02 and DESTINY-Breast06 in HR+/HER2– Breast Cancer
      Comparing ADCs in HR+/HER2– Breast Cancer Without Head-to-Head Trials
      Comparing ADCs in HR+/HER2– Breast Cancer Without Head-to-Head Trials
      Navigating Treatment/Testing Decisions in Metastatic HR+/HER2– Breast Cancer
      Navigating Treatment/Testing Decisions in Metastatic HR+/HER2– Breast Cancer
      Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
      Breast Cancer Disparities May Fuel Guideline-Concordant Care Improvements
      Related Content
      TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC

      TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC

      Radhika Appaya;Debasish Tripathy;Dejan Juric;Sonia Pernas;Francois Clement Bidard;Kevin Perraud;Louise Emmett;Ana Sofia Ferreira
      June 22nd 2025
      Article

      Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

      Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

      Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
      April 21st 2025
      Podcast

      Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

      Breast oncologist Jade E. Jones, MD, discussed the role of PARP inhibition and antibody-drug conjugates in treating patients with metastatic breast cancer.

      Optimizing Therapy Sequencing in HR+/HER2- or Triple-Negative Breast Cancer

      Roman Fabbricatore
      June 21st 2025
      Article
      Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

      SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

      Paolo Tarantino, MD;Matteo Lambertini, MD
      January 13th 2025
      Podcast

      Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

      27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

      27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

      Aditya Bardia, MD, MPH;Javier Cortés, MD;Francois Clement Bidard;Guillermo Streich;José García-Sáenz;Janice Lu, MD, PhD ;Giulia Tonini;Simona Scartoni;Alessandro Paoli;Alessio Fiascarelli;Alessandro Bressan;Monica Binaschi;Tomer Wasserman;Virginia Kaklamani, MD, DSc
      June 19th 2025
      Article
      TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

      TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

      Aditya Bardia, MD, MPH;Virginia Kaklamani, MD, DSc;Joyce A. O’Shaughnessy;Peter Schmid, MD;J. Thaddeus Beck,;Michelino De Laurentiis;Guiseppe Curigliano;Hope S. Rugo, MD;Carlos Barcenas;William J. Gradishar, MD;Michail Ignatiadis;David Cameron;Giulia Tonini;Simona Scartoni;Jennifer Crozier;Leo Viana Nicacio;Tomer Wasserman;Sara M. Tolaney, MD, MPH
      June 18th 2025
      Article